Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Misoprostol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 known ✓ | P43115 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PTGIR | P43119 | 9/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Misoprostol SCHEMBL10328461 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL17510372 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL22039860 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL22381095 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL24176879 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL20646583 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL24176880 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL22381098 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL23352527 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL21423327 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18423 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4731082-A1 | METHOD AND SYSTEM FOR FETAL MONITORING AND TREATMENT | FMSA Inc (US) | 2026-04-29 | — | — | EP | claimed |
| US-12594237-B2 | Mucoadhesive gel composition | Viramal Limited (GB) | 2026-04-07 | — | — | US | claimed |
| EP-4704815-A1 | A FLOATING DRUG DELIVERY SYSTEM FOR SOLID FORMS OF SALTS USED IN BOWEL CLEANSING PRODUCTS | Dark Canyon Laboratories, LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569437-B2 | Disease-site-specific liposomal formulation | OSAKA UNIVERSITY (JP) | 2026-03-10 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| CN-121583444-A | Misoprostol cervical ripening optimized administration method based on PopPK model | 北京大学第三医院（北京大学第三临床医学院） | 2026-02-27 | — | — | CN | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| WO-1992000739-A1 | 3-PHENYL-5,6-DIHYDROBENZ[C]ACRIDINE-7-CARBOXYLIC ACIDS AND RELATED COMPOUNDS AS IMMUNOSUPPRESIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-23 | — | — | WO | claimed |
| WO-1991019498-A1 | TREATMENT OF ORGAN TRANSPLANTATION REJECTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-26 | — | — | WO | claimed |
| WO-1991016895-A1 | PHARMACEUTICAL COMPOSITION | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | claimed |
| WO-1991016896-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING PAIN | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | claimed |
| WO-1991016886-A1 | PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN AND A PROSTAGLANDIN | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | claimed |
| EP-0445948-A2 | Prostaglandins for inhibiting cartilage damage | G.D. Searle & Co. (US) | 1991-09-11 | — | — | EP | claimed |
| US-5015481-A | Non-steroidal Antiinflammatory Agent, Prostaglandin Derivative And Hydroxypropyl Methyl Cellulose | G. D. SEARLE & CO. (US) | 1991-05-14 | — | — | US | claimed |
| EP-0372541-A1 | Method for imparting immunosuppression | G.D. Searle & Co. (US) | 1990-06-13 | — | — | EP | claimed |
| EP-0129908-A1 | Use of misoprostol to manufacture cholesterol lowering medicines | G.D. Searle & Co. (US) | 1985-01-02 | — | — | EP | claimed |
| US-4459310-A | 16-ALKYL-16-HYDROXY PROSTAGLANDINS | G.D. SEARLE & CO. (US) | 1984-07-10 | — | — | US | claimed |